Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 15, 2019. The report discloses the granting of Conditional Share Awards to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) on February 13, 2019, under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on equity compensation transactions.
| Executive | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Ms E Walmsley | Chief Executive Officer | Ordinary Shares | 61,813 | £15.468 |
| Dr H Barron | Chief Scientific Officer | Ordinary Shares | 37,120 | $40.53 |
| Mr R Connor | President, Global Vaccines | Ordinary Shares | 16,223 | £15.468 |
| Mr S Dingemans | Chief Financial Officer | Ordinary Shares | 44,215 | £15.468 |
| Mr J Ford | SVP & General Counsel | ADSs | 3,202 | $40.53 |
| Mr N Hirons | SVP, Global Ethics | Ordinary Shares | 6,801 | £15.468 |
| Mr L Miels | President, Global Pharmaceuticals | Ordinary Shares | 17,252 | £15.468 |
| Mr B McNamara | CEO, Consumer Healthcare | ADSs | 6,251 | $40.53 |
| Mr D Redfern | Chief Strategy Officer | Ordinary Shares | 15,331 | £15.468 |
| Mr R Simard | President, Supply Chain | Ordinary Shares | 5,540 | £15.468 |
| Ms C Thomas | SVP, Human Resources | Ordinary Shares | 13,098 | £15.468 |
| Mr P Thomson | President, Global Affairs | Ordinary Shares | 8,972 | £15.468 |
| Ms K Terrell | Chief Digital & Technology Officer | ADSs | 7,899 | $40.53 |
Material Changes
The filing notes a structural change to the compensation plan effective from 2018: DABP Matching Awards are no longer granted. Executive Directors are required to defer 50% of any bonus earned into shares for three years, while other participants defer 25%.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The awards are conditional and subject to a three-year deferral period. The share volumes listed are exclusive of dividend reinvestment that will accrue during this period.
Investor Verification Checklist
- Verify the total number of shares/ADSs granted to ensure alignment with the company's annual compensation disclosure.
- Confirm the deferral terms (50% for Executives, 25% for others) and the three-year vesting period.
- Note that the filing does not include financial performance data; refer to the most recent Form 20-F or quarterly earnings release for revenue and profit metrics.
- Check for subsequent filings regarding the vesting or release of these deferred awards.